Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a potentially predictive biomarker
Diffuse, Large B-Cell, Lymphoma
DRUG: Copanlisib (Aliqopa, BAY80-6946)
Objective Response Rate (ORR) in Total Population Based on Investigator Assessment, The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The primary efficacy overall response assessment was based on investigator assessment of response., From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months)|ORR by CD79b Status Based on Investigator Assessment, The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The primary efficacy overall response assessment was based on investigator assessment of response., From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months)|ORR by DLBCL/COO Subtype Based on Investigator Assessment, The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The primary efficacy overall response assessment was based on investigator assessment of response., From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months)
Duration of Response (DOR) in Total Population, The duration of response (DOR) was defined as the time from the date of first observed overall response (CR or PR) until radiological PD or death due to any cause, whichever was earlier. DOR was defined for responders only (i.e. participants with a best response of CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|DOR by CD79b Status, The duration of response (DOR) was defined as the time from the date of first observed overall response (CR or PR) until radiological PD or death due to any cause, whichever was earlier. DOR was defined for responders only (i.e. participants with a best response of CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|DOR by DLBCL/COO Subtype, The duration of response (DOR) was defined as the time from the date of first observed overall response (CR or PR) until radiological PD or death due to any cause, whichever was earlier. DOR was defined for responders only (i.e. participants with a best response of CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|Progression-free Survival (PFS) in Total Population, The progression-free survival (PFS) was defined as the time from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|PFS by CD79b Status, The progression-free survival (PFS) was defined as the time from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|PFS by DLBCL/COO Subtype, The progression-free survival (PFS) was defined as the time from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|Overall Survival (OS) in Total Population, The overall survival (OS) was defined as the time from date of start of study treatment until death from any cause., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|OS by CD79b Status, The overall survival (OS) was defined as the time from date of start of study treatment until death from any cause., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|OS by DLBCL/COO Subtype, The overall survival (OS) was defined as the time from date of start of study treatment until death from any cause., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|Duration of Stable Disease (DOSD) in Total Population, The duration of stable disease (DOSD) was defined as the time (in days) from date of start of study treatment to radiological PD or death due to any cause, whichever was earlier. The DOSD was only evaluated in participants failing to achieve a best response of CR or PR, but who achieved SD (stable disease), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|Disease Control Rate (DCR) in Total Population, The disease control rate (DCR) was defined as the percentage of participants who had a best response rating of CR, PR, or SD that was achieved during treatment or within 30 days after termination of study drug. The tumor response was based on investigator assessment according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|DCR by CD79b Status, The disease control rate (DCR) was defined as the percentage of participants who had a best response rating of CR, PR, or SD that was achieved during treatment or within 30 days after termination of study drug. The tumor response was based on investigator assessment according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|DCR by DLBCL/COO Subtype, The disease control rate (DCR) was defined as the percentage of participants who had a best response rating of CR, PR, or SD that was achieved during treatment or within 30 days after termination of study drug. The tumor response was based on investigator assessment according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs), A TEAE was defined as any event arising or worsening after the start of study drug administration until 30 days after the last application., From start of test drug to 30 days after the last test drug intake, assessed up to 2 years after the last participant's first treatment or the last participant dies (whichever occurs first), with an average of 15 weeks for individual participant
Time to Response (TTR) in Total Population, The time to response (TTR) was defined as the time (days) from start of study treatment to the date of first observed response (first measured CR or PR). TTR was defined for responders only (i.e. participants with CR or PR), based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT., From start of study treatment assessed up to 2 years after the last participant's first treatment or the last participant dies, whichever occurs first|ORR in Total Population Based on Central Imaging Review, The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The overall response assessment for this outcome measure was based on central imaging review., From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months)|ORR by CD79b Status Based on Central Imaging Review, The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The overall response assessment for this outcome measure was based on central imaging review., From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months)|ORR by DLBCL/COO Subtype Based on Central Imaging Review, The objective response rate (ORR) was defined as the percentage of participants who had at least one post-baseline overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano Classification, 2014 and assessed by CT/MRI/PET-CT. The overall response assessment for this outcome measure was based on central imaging review., From start of study treatment assessed up to 24 weeks after the last participant fully evaluable for the primary endpoint started treatment (about 12 months)
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a potentially predictive biomarker